Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17729177 | 0.78 | CDK1 (0.44) | ADORA1ADORA2AYTHDC1KDM4EALDH1A1 | |
| SCHEMBL16247699 | 0.78 | ADORA1 (0.44) | ADORA1ADORA2AYTHDC1KDM4EALDH1A1 | |
| SCHEMBL17741050 | 0.78 | ADORA1 (0.44) | ADORA1ADORA2AYTHDC1KDM4EALDH1A1 | |
| SCHEMBL13548807 | 0.78 | ADORA2A (0.53) | ADORA1ADORA2AYTHDC1KDM4EALDH1A1 | |
| SCHEMBL23331997 | 0.75 | ADORA1 (0.42) | ADORA1ADORA2AYTHDC1KDM4EALDH1A1 | |
| SCHEMBL21849186 | 0.75 | ADORA1 (0.42) | ADORA1ADORA2AYTHDC1KDM4EALDH1A1 | |
| SCHEMBL13437849 | 0.75 | ADORA1 (0.42) | ADORA1ADORA2AYTHDC1KDM4EALDH1A1 | |
| SCHEMBL784184 | 0.75 | ADORA2A (0.50) | ADORA1ADORA2ACDK1PDE4APDE4B | |
| SCHEMBL24896143 | 0.75 | YTHDC1 (0.51) | ADORA1ADORA2AYTHDC1KDM4EALDH1A1 | |
| SCHEMBL17898191 | 0.75 | ADORA1 (0.42) | ADORA1ADORA2AYTHDC1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118786130-A | Substituted imidazopyridinyl compounds useful as TLR9 inhibitors | 百时美施贵宝公司 | 2024-10-15 | — | — | CN | disclosed |
| WO-2022174253-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2021050964-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
| EP-3686196-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | Hangzhou Innogate Pharma Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| WO-2020065614-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| EP-3294732-B1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | GILEAD SCIENCES INC (US) | 2019-09-25 | — | — | EP | disclosed |
| EP-3294732-B1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | GILEAD SCIENCES INC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-9951065-B2 | Benzimidazole and imadazopyridine carboximidamide compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951065-B2 | Benzimidazole and imadazopyridine carboximidamide compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3294732-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Gilead Sciences, Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20100144591-A1 | BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-7713944-B2 | Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1836211-B1 | MACROLIDES | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-7462600-B2 | Macrolides | PFIZER INC (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080207541-A1 | Contacting a eukaryotic cell with a mixed backbone oligonucleotide with a first region that forms a substrate for cleavage by an RNase and a second region which does not, and a transition moiety which modulates the transmission of the conformation of said second region into the first region | IONIS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
| EP-1921141-A1 | NOVEL ARTIFICIAL BASE PAIR AND USE THEREOF | Riken (JP) | 2008-05-14 | — | — | EP | disclosed |
| US-20070276139-A1 | Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis | ISIS PHARMACEUTICALS, INC. | 2007-11-29 | — | — | US | disclosed |
| EP-1836211-A1 | MACROLIDES | Pfizer Products Incorporated (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006067589-A1 | MACROLIDES | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135447-A1 | Macrolides | CHUPAK LOUIS S | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207541-A1 | Contacting a eukaryotic cell with a mixed backbone oligonucleotide with a first region that forms a substrate for cleavage by an RNase and a second region which does not, and a transition moiety which modulates the transmission of the conformation of said second region into the first region | RNASEH1, NSUN3, RNASEL | ADORA1 3106/4885ADORA2A 2420/4885YTHDC1 144/4885 |
| US-20060135447-A1 | Macrolides | LCAT, NOP2, HDAC6 | ADORA1 2711/4885ADORA2A 1832/4885YTHDC1 2830/4885 |
| US-20070276139-A1 | Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis | RPP30, NOP10, NR0B1 | ADORA1 690/4885ADORA2A 598/4885YTHDC1 2201/4885 |
| US-20100144591-A1 | BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GK, GCK | ADORA1 3488/4885ADORA2A 3567/4885YTHDC1 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.